New combo therapy aims to outsmart BRCA breast cancer
Disease control
Recruiting now
This study is for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA1 or BRCA2 gene mutation. It tests whether adding a new oral drug called elacestrant to the standard treatment olaparib can help keep the cancer from growing longer …
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated May 26, 2026 12:11 UTC